Shopping Cart 0
Cart Subtotal
USD 0

Progressive Supranuclear Palsy-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Progressive Supranuclear Palsy-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Progressive Supranuclear Palsy-Pipeline Review, H2 2017, provides an overview of the Progressive Supranuclear Palsy (Central Nervous System) pipeline landscape.

Progressive supranuclear palsy, also called Steele-Richardson-Olszewski syndrome is a rare neurodegenerative disease that leads to difficulty with balance, movement, vision, speech and swallowing. Symptoms include fatigue, headaches, dizziness, depression, Parkinsonism, behavioral, cognitive, and gait disturbances that cause imbalance and arthralgias. The only proven risk factor for progressive supranuclear palsy is age. Treatment includes anticholinergic medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Progressive Supranuclear Palsy-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Progressive Supranuclear Palsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Progressive Supranuclear Palsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Progressive Supranuclear Palsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Unknown stages are 1, 3, 5, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Progressive Supranuclear Palsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Progressive Supranuclear Palsy (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Progressive Supranuclear Palsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Progressive Supranuclear Palsy (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Progressive Supranuclear Palsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Progressive Supranuclear Palsy (Central Nervous System)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Progressive Supranuclear Palsy (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it'smost promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Progressive Supranuclear Palsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Progressive Supranuclear Palsy-Overview

Progressive Supranuclear Palsy-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Progressive Supranuclear Palsy-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Progressive Supranuclear Palsy-Companies Involved in Therapeutics Development

AB Science SA

AbbVie Inc

AlzProtect SAS

Asceneuron SA

Biogen Inc

Cortice Biosciences Inc

Intellect Neurosciences Inc

K-Stemcell Co Ltd

Merck & Co Inc

Prana Biotechnology Ltd

TauRx Therapeutics Ltd

UCB SA

Progressive Supranuclear Palsy-Drug Profiles

ABBV-8E12-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASN-120290-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZP-2006-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DC-TAB-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DPC-016-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gosuranemab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

masitinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-8719-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit Tau for Progressive Supranuclear Palsy-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PBT-434-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Spinal Cord Injury, Alzheimer's Disease, Progressive Supranuclear Palsy and Cerebral Palsy-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TauC-3-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tolfenamic acid-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TPI-287-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRx-0237-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Progressive Supranuclear Palsy-Dormant Projects

Progressive Supranuclear Palsy-Product Development Milestones

Featured News & Press Releases

Nov 03, 2017: Cortice Biosciences Announces Presentation of Results from Placebo-Controlled Phase 1 Clinical Trials Evaluating TPI 287 for Treatment of Alzheimer'sDisease and Related Tauopathies

May 04, 2017: AlzProtect : The American Food and Drug Administration (FDA) Has Granted AZP2006 the Orphan Drug Designation for the Treatment of Progressive Supranuclear Palsy (PSP)

Apr 04, 2017: Asceneuron Receives Approval for Phase I Study of Oral Tau Inhibitor

Jan 25, 2017: AbbVie Initiates Phase 2 Clinical Trial Programs for ABBV-8E12, an Investigational Anti-Tau Antibody, in Early Alzheimer's Disease and Progressive Supranuclear Palsy

Oct 13, 2016: C2N Diagnostics Completes Phase 1 Clinical Study of C2N-8E12 (ABBV-8E12) Among Individuals with Progressive Supranuclear Palsy

Jul 17, 2015: C2N And Abbvie Announce FDA Orphan Drug Designation Of C2N-8E12 (ABBV-8E12) For The Treatment Of Progressive Supranuclear Palsy

Jul 07, 2014: Cortice Announces Enrollment of a Phase 1 Clinical Trial Evaluating TPI 287 in Rare Tauopathy Diseases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Progressive Supranuclear Palsy, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Progressive Supranuclear Palsy, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Progressive Supranuclear Palsy-Pipeline by AB Science SA, H2 2017

Progressive Supranuclear Palsy-Pipeline by AbbVie Inc, H2 2017

Progressive Supranuclear Palsy-Pipeline by AlzProtect SAS, H2 2017

Progressive Supranuclear Palsy-Pipeline by Asceneuron SA, H2 2017

Progressive Supranuclear Palsy-Pipeline by Biogen Inc, H2 2017

Progressive Supranuclear Palsy-Pipeline by Cortice Biosciences Inc, H2 2017

Progressive Supranuclear Palsy-Pipeline by Intellect Neurosciences Inc, H2 2017

Progressive Supranuclear Palsy-Pipeline by K-Stemcell Co Ltd, H2 2017

Progressive Supranuclear Palsy-Pipeline by Merck & Co Inc, H2 2017

Progressive Supranuclear Palsy-Pipeline by Prana Biotechnology Ltd, H2 2017

Progressive Supranuclear Palsy-Pipeline by TauRx Therapeutics Ltd, H2 2017

Progressive Supranuclear Palsy-Pipeline by UCB SA, H2 2017

Progressive Supranuclear Palsy-Dormant Projects, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

AB Science SA

AbbVie Inc

AlzProtect SAS

Asceneuron SA

Biogen Inc

Cortice Biosciences Inc

Intellect Neurosciences Inc

K-Stemcell Co Ltd

Merck & Co Inc

Prana Biotechnology Ltd

TauRx Therapeutics Ltd

UCB SA